Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 3/2008

01-12-2008

The influence of acute-phase levels of haemostatic factors on reperfusion and mortality in patients with acute myocardial infarction treated with streptokinase

Authors: Johan B. Nilsson, Kurt Boman, Jan-Håkan Jansson, Torbjörn Nilsson, Ulf Näslund

Published in: Journal of Thrombosis and Thrombolysis | Issue 3/2008

Login to get access

Abstract

Background The fibrinolytic system and von Willebrand factor (vWF) have been shown to play a role as risk factors for myocardial infarction. We performed this prospective cohort study to determine if components in the fibrinolytic system or vWF before or during treatment of AMI with streptokinase (SK) could predict reperfusion, recurrent ischaemia, reinfarction or mortality at one year, or mortality at five years. Reperfusion and recurrent ischaemia were assessed by continuous vectorcardiography. The setting was Umeå university hospital and Skellefteå county hospital, Sweden. Results 139 patients were included; successful reperfusion was obtained in 53%. tPA activity, PAI-activity, PAI-mass concentration and vWF were analysed immediately on arrival and after 4 and 10 h. High fibrinolytic activity, measured as tPA activity > 25 U/L after the start of treatment, was associated with reperfusion. No significant associations between pre-treatment levels of the fibrinolytic variables or vWF and reperfusion or recurrent ischaemia were found. Elevated levels of PAI-1 mass concentration and PAI-1 activity after the start of SK treatment were associated with a higher risk for death at one year, but not at five years. High levels of vWF were associated with worse prognosis but not when corrected for age. Conclusion Pre-treatment levels of PAI-1, vWF and tPA activity showed no association with reperfusion or recurrent ischaemia. Elevated levels of PAI-1 activity after the start of treatment were associated with worse prognosis.
Literature
1.
go back to reference Van de Werf F, Ardissino D, Betriu A et al (2003) Management of acute myocardial infarction in patients presenting with ST-segment elevation. The task force on the management of acute myocardial infarction of the European society of cardiology. Eur Heart J 24(1):28–66PubMedCrossRef Van de Werf F, Ardissino D, Betriu A et al (2003) Management of acute myocardial infarction in patients presenting with ST-segment elevation. The task force on the management of acute myocardial infarction of the European society of cardiology. Eur Heart J 24(1):28–66PubMedCrossRef
2.
go back to reference Boersma E (2006) Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J 27(7):779–788PubMedCrossRef Boersma E (2006) Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J 27(7):779–788PubMedCrossRef
3.
go back to reference Keeley EC, Boura JA, Grines CL (2003) Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361(9351):13–20PubMedCrossRef Keeley EC, Boura JA, Grines CL (2003) Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361(9351):13–20PubMedCrossRef
4.
go back to reference The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. (1993) The GUSTO angiographic investigators. N Engl J Med 329(22):1615–1622 The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. (1993) The GUSTO angiographic investigators. N Engl J Med 329(22):1615–1622
5.
go back to reference An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. (1993) The GUSTO investigators. N Engl J Med 329(10):673–682 An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. (1993) The GUSTO investigators. N Engl J Med 329(10):673–682
6.
go back to reference Nilsson JB, Nilsson TK, Jansson JH, Boman K, Söderberg S, Näslund U (2002) The effect of streptokinase neutralizing antibodies on fibrinolytic activity and reperfusion following streptokinase treatment in acute myocardial infarction. J Intern Med 252(5):405–411PubMedCrossRef Nilsson JB, Nilsson TK, Jansson JH, Boman K, Söderberg S, Näslund U (2002) The effect of streptokinase neutralizing antibodies on fibrinolytic activity and reperfusion following streptokinase treatment in acute myocardial infarction. J Intern Med 252(5):405–411PubMedCrossRef
7.
go back to reference Nilsson JB, Nilsson TK, Jansson JH, Boman K, Thögerssen AM, Näslund U (1997) Relationship between fibrinolytic activity following streptokinase treatment in acute myocardial infarction and vectorcaardiographic signs of reperfusion. Fibrinolysis and Proteolysis 11(4):193–199CrossRef Nilsson JB, Nilsson TK, Jansson JH, Boman K, Thögerssen AM, Näslund U (1997) Relationship between fibrinolytic activity following streptokinase treatment in acute myocardial infarction and vectorcaardiographic signs of reperfusion. Fibrinolysis and Proteolysis 11(4):193–199CrossRef
8.
go back to reference Cortellaro M, Cofrancesco E, Boschetti C et al (1993) Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. A case-control study. The PLAT Group. Arterioscler Thromb 13(10):1412–1417PubMed Cortellaro M, Cofrancesco E, Boschetti C et al (1993) Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. A case-control study. The PLAT Group. Arterioscler Thromb 13(10):1412–1417PubMed
9.
go back to reference Hamsten A, de Faire U, Walldius G et al (1987) Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 2(8549):3–9PubMedCrossRef Hamsten A, de Faire U, Walldius G et al (1987) Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 2(8549):3–9PubMedCrossRef
10.
go back to reference Thögersen AM, Jansson JH, Boman K et al (1998) High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98(21):2241–2247PubMed Thögersen AM, Jansson JH, Boman K et al (1998) High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98(21):2241–2247PubMed
11.
go back to reference Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC (1995) Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European concerted action on thrombosis and disabilities angina pectoris study group. N Engl J Med 332(10):635–641PubMedCrossRef Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC (1995) Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European concerted action on thrombosis and disabilities angina pectoris study group. N Engl J Med 332(10):635–641PubMedCrossRef
12.
go back to reference Jansson JH, Nilsson TK, Olofsson BO (1991) Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 12(2):157–161PubMed Jansson JH, Nilsson TK, Olofsson BO (1991) Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 12(2):157–161PubMed
13.
go back to reference Jansson JH, Nilsson TK, Johnson O (1991) von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 66(5):351–355PubMedCrossRef Jansson JH, Nilsson TK, Johnson O (1991) von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 66(5):351–355PubMedCrossRef
14.
go back to reference Wiman B, Andersson T, Hallqvist J, Reuterwall C, Ahlbom A, deFaire U (2000) Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler Thromb Vasc Biol 20(8):2019–2023PubMed Wiman B, Andersson T, Hallqvist J, Reuterwall C, Ahlbom A, deFaire U (2000) Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler Thromb Vasc Biol 20(8):2019–2023PubMed
15.
go back to reference Barbash GI, Hod H, Roth A et al (1989) Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction. Am J Cardiol 64(19):1231–1235PubMedCrossRef Barbash GI, Hod H, Roth A et al (1989) Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction. Am J Cardiol 64(19):1231–1235PubMedCrossRef
16.
go back to reference Sane DC, Stump DC, Topol EJ et al (1991) Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction. Thromb Haemost 65(3):275–279PubMed Sane DC, Stump DC, Topol EJ et al (1991) Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction. Thromb Haemost 65(3):275–279PubMed
17.
go back to reference Sinkovic A (1998) Pretreatment plasminogen activator inhibitor-1 (PAI-1) levels and the outcome of thrombolysis with streptokinase in patients with acute myocardial infarction. Am Heart J 136(3):406–411PubMedCrossRef Sinkovic A (1998) Pretreatment plasminogen activator inhibitor-1 (PAI-1) levels and the outcome of thrombolysis with streptokinase in patients with acute myocardial infarction. Am Heart J 136(3):406–411PubMedCrossRef
18.
go back to reference Paganelli F, Alessi MC, Morange P, Maixent JM, Levy S, Vague IJ (1999) Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery. Thromb Haemost 82(1):104–108PubMed Paganelli F, Alessi MC, Morange P, Maixent JM, Levy S, Vague IJ (1999) Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery. Thromb Haemost 82(1):104–108PubMed
19.
go back to reference Dellborg M, Riha M, Swedberg K (1991) Dynamic QRS-complex and ST-segment monitoring in acute myocardial infarction during recombinant tissue-type plasminogen activator therapy. The TEAHAT Study Group. Am J Cardiol 67(5):343–349PubMedCrossRef Dellborg M, Riha M, Swedberg K (1991) Dynamic QRS-complex and ST-segment monitoring in acute myocardial infarction during recombinant tissue-type plasminogen activator therapy. The TEAHAT Study Group. Am J Cardiol 67(5):343–349PubMedCrossRef
20.
go back to reference Dellborg M, Steg PG, Simoons M et al (1995) Vectorcardiographic monitoring to assess early vessel patency after reperfusion therapy for acute myocardial infarction. Eur Heart J 6(1):21–29 Dellborg M, Steg PG, Simoons M et al (1995) Vectorcardiographic monitoring to assess early vessel patency after reperfusion therapy for acute myocardial infarction. Eur Heart J 6(1):21–29
21.
go back to reference Jensen SM, Johansson G, Osterman G, Reiz S, Näslund U (1994) On-line computerized vectorcardiography monitoring of myocardial ischemia during coronary angioplasty: comparison with 12-lead electrocardiography. Coron Artery Dis 5(6):507–514PubMed Jensen SM, Johansson G, Osterman G, Reiz S, Näslund U (1994) On-line computerized vectorcardiography monitoring of myocardial ischemia during coronary angioplasty: comparison with 12-lead electrocardiography. Coron Artery Dis 5(6):507–514PubMed
22.
go back to reference Jensen SM, Nilsson JB, Näslund U (2003) Early vectorcardiographic monitoring provides prognostic information in patients with ST-elevation myocardial infarction. Scand Cardiovasc J 37(3):135–140PubMedCrossRef Jensen SM, Nilsson JB, Näslund U (2003) Early vectorcardiographic monitoring provides prognostic information in patients with ST-elevation myocardial infarction. Scand Cardiovasc J 37(3):135–140PubMedCrossRef
23.
go back to reference Johanson P, Swedberg K, Dellborg M (2001) ST variability during the first 4 hours of acute myocardial infarction predicts 1-year mortality. Ann Noninvasive Electrocardiol 6(3):198–202PubMedCrossRef Johanson P, Swedberg K, Dellborg M (2001) ST variability during the first 4 hours of acute myocardial infarction predicts 1-year mortality. Ann Noninvasive Electrocardiol 6(3):198–202PubMedCrossRef
24.
go back to reference Näslund U, Häggmark S, Johansson G, Reiz S (1993) Quantification of myocardium at risk and detection of reperfusion by dynamic vectorcardiographic ST segment monitoring in a pig occlusion-reperfusion model. Cardiovasc Res 27(12):2170–2178PubMedCrossRef Näslund U, Häggmark S, Johansson G, Reiz S (1993) Quantification of myocardium at risk and detection of reperfusion by dynamic vectorcardiographic ST segment monitoring in a pig occlusion-reperfusion model. Cardiovasc Res 27(12):2170–2178PubMedCrossRef
25.
go back to reference Näslund U, Häggmark S, Johansson G, Reiz S (1993) Ischaemia and reperfusion induced transient QRS vector changes: relationship to size of the ischaemic territory. Cardiovasc Res 27(2):327–333PubMedCrossRef Näslund U, Häggmark S, Johansson G, Reiz S (1993) Ischaemia and reperfusion induced transient QRS vector changes: relationship to size of the ischaemic territory. Cardiovasc Res 27(2):327–333PubMedCrossRef
26.
go back to reference Sederholm M, Erhardt L, Sjögren A (1983) Continuous vectorcardiography in acute myocardial infarction. Natural course of ST and QRS vectors. Int J Cardiol 4(1):53–63PubMedCrossRef Sederholm M, Erhardt L, Sjögren A (1983) Continuous vectorcardiography in acute myocardial infarction. Natural course of ST and QRS vectors. Int J Cardiol 4(1):53–63PubMedCrossRef
27.
go back to reference Frank E (1956) An accurate, clinically practical system for spatial vectorcardiography. Circulation 13(5):737–749PubMed Frank E (1956) An accurate, clinically practical system for spatial vectorcardiography. Circulation 13(5):737–749PubMed
28.
go back to reference Jensen SM, Häggmark S, Johansson G, Näslund U (1997) On-line computerized vectorcardiography: influence of body position, heart rate, radiographic contrast fluid and myocardial ischemia. Cardiology 88(6):576–584PubMedCrossRef Jensen SM, Häggmark S, Johansson G, Näslund U (1997) On-line computerized vectorcardiography: influence of body position, heart rate, radiographic contrast fluid and myocardial ischemia. Cardiology 88(6):576–584PubMedCrossRef
29.
go back to reference Rånby M, Sundell IB, Nilsson TK (1989) Blood collection in strong acidic citrate anticoagulant used in a study of dietary influence on basal tPA activity. Thromb Haemost 62(3):917–922PubMed Rånby M, Sundell IB, Nilsson TK (1989) Blood collection in strong acidic citrate anticoagulant used in a study of dietary influence on basal tPA activity. Thromb Haemost 62(3):917–922PubMed
30.
go back to reference Chmielewska J, Wiman B (1986) Determination of tissue plasminogen activator and its “fast” inhibitor in plasma. Clin Chem 32(3):482–485PubMed Chmielewska J, Wiman B (1986) Determination of tissue plasminogen activator and its “fast” inhibitor in plasma. Clin Chem 32(3):482–485PubMed
31.
go back to reference Rånby M, Bergsdorf N, Nilsson T, Mellbring G, Winblad B, Bucht G (1986) Age dependence of tissue plasminogen activator concentrations in plasma, as studied by an improved enzyme-linked immunosorbent assay. Clin Chem 32(12):2160–2165PubMed Rånby M, Bergsdorf N, Nilsson T, Mellbring G, Winblad B, Bucht G (1986) Age dependence of tissue plasminogen activator concentrations in plasma, as studied by an improved enzyme-linked immunosorbent assay. Clin Chem 32(12):2160–2165PubMed
32.
go back to reference Cejka J (1982) Enzyme immunoassay for factor VIII-related antigen. Clin Chem 28(6):1356–1358PubMed Cejka J (1982) Enzyme immunoassay for factor VIII-related antigen. Clin Chem 28(6):1356–1358PubMed
33.
go back to reference Gray RP, Yudkin JS, Patterson DL (1993) Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: a role for plasminogen activator inhibitor? Br Heart J 70(6):530–536PubMedCrossRef Gray RP, Yudkin JS, Patterson DL (1993) Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: a role for plasminogen activator inhibitor? Br Heart J 70(6):530–536PubMedCrossRef
34.
go back to reference Potter van Loon BJ, Rijken DC, Brommer EJ, van der Maas AP (1992) The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility. Thromb Haemost 67(1):101–105PubMed Potter van Loon BJ, Rijken DC, Brommer EJ, van der Maas AP (1992) The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility. Thromb Haemost 67(1):101–105PubMed
35.
go back to reference Mlynarska A, Waszyrowski T, Kasprzak JD (2006) Increase in plasma plasminogen activators inhibitor type 1 concentration after fibrinolytic treatment in patients with acute myocardial infarction is associated with 4G/5G polymorphism of PAI-1 gene. J Thromb Haemost 4(6):1361–1366PubMedCrossRef Mlynarska A, Waszyrowski T, Kasprzak JD (2006) Increase in plasma plasminogen activators inhibitor type 1 concentration after fibrinolytic treatment in patients with acute myocardial infarction is associated with 4G/5G polymorphism of PAI-1 gene. J Thromb Haemost 4(6):1361–1366PubMedCrossRef
36.
go back to reference Urano T, Sumiyoshi K, Pietraszek MH, Takada Y, Takada A (1991) PAI-1 plays an important role in the expression of t-PA activity in the euglobulin clot lysis by controlling the concentration of free t-PA. Thromb Haemost 66(4):474–478PubMed Urano T, Sumiyoshi K, Pietraszek MH, Takada Y, Takada A (1991) PAI-1 plays an important role in the expression of t-PA activity in the euglobulin clot lysis by controlling the concentration of free t-PA. Thromb Haemost 66(4):474–478PubMed
37.
go back to reference Lip GY, Blann A (1997) von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 34(2):255–265PubMedCrossRef Lip GY, Blann A (1997) von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 34(2):255–265PubMedCrossRef
38.
go back to reference Morange PE, Simon C, Alessi MC et al (2004) Endothelial cell markers and the risk of coronary heart disease: the PROSPECTIVE Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 109(11):1343–1348PubMedCrossRef Morange PE, Simon C, Alessi MC et al (2004) Endothelial cell markers and the risk of coronary heart disease: the PROSPECTIVE Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 109(11):1343–1348PubMedCrossRef
Metadata
Title
The influence of acute-phase levels of haemostatic factors on reperfusion and mortality in patients with acute myocardial infarction treated with streptokinase
Authors
Johan B. Nilsson
Kurt Boman
Jan-Håkan Jansson
Torbjörn Nilsson
Ulf Näslund
Publication date
01-12-2008
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 3/2008
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-007-0086-9

Other articles of this Issue 3/2008

Journal of Thrombosis and Thrombolysis 3/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine